Pricing
  1. JP-listed companies
  2. TAKARA BIO INC.
  3. Financials
  4. Gross profit

TAKARA BIO INC.【JP:4974】

Market cap
¥138.1B
P/E ratio
-15.3x
Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross profit (Million JPY)YoY (%)
Mar 31, 202526,067-3.13%
Mar 31, 202426,908-39.89%
Mar 31, 202344,765-9.03%
Mar 31, 202249,211+54.40%
Mar 31, 202131,872+51.02%
Mar 31, 202021,105+2.03%
Mar 31, 201920,685+10.88%
Mar 31, 201818,655+10.05%
Mar 31, 201716,952+3.85%
Mar 31, 201616,323+18.05%
Mar 31, 201513,827

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)